Myelodyspastics Syndrome (MDS) Prognosis: Risk Scoring Systems
It is not possible to give a precise outcome for you as an individual patient but this scoring system is useful for a discussion about the future and the options for treatment that may help.
As research, understanding and information about MDS is constantly evolving and improving, the data gathered enables clinicians to categorise sub-types of MDS even more precisely.
First, the basic IPSS was developed with 4 MDS risk categories: Low risk, Intermediate 1, Intermediate 2, High-risk
Then, in 2013, it was improved to the IPSS-R, which has been the standard since 2015-2016 and consists of 5 categories: Very low-risk, Low-risk, Intermediate, High-risk, Very high-risk.
Upcoming Developments: Incorporating Genetic Information into Risk Scores
We are expecting the IPSS-Mol. This will take into account research and results on MDS gene mutations and provide a further layer of details, possibly telling us which patients may respond better to specific treatments, or for whom a transplant should be attempted earlier – or perhaps avoided all together.
It is hoped the IPSS-Mol may reduce the difficult uncertainty factor a little further – which would be another important step forward in MDS care.
Dr Shahram Kordasti, Haematologist, King’s College London, explains the role of the immune system in MDS and how it can be used to predict risk and response to treatment
Download this presentation and learn more about how long it takes to diagnose MDS, the risk scoring of the different types of MDS and much more.